Abstract B33: The membrane associated cyclin D1 promotes contact-independent growth via phosphorylation of Akt1 Ser 473

The serine threonine kinase Akt plays a pivotal role in the control of cellular metabolism, survival, growth and cellular migration. Cyclin D1 encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates pRb, to promote cell cycle progression and functions as a nuclear collaborative oncogene. Herein, genetic deletion of cyclin D1 reduced and overexpression induced Akt1 activity in tissue culture and in vivo. Endogenous cyclin D1 augmented both the rate of onset and maximal cellular Akt1 activity. The cytoplasmic membrane-associated pool of cyclin D1, augmented Akt1 kinase activity, to thereby induce cell cycle progression, cellular migration, proliferation and contact independent growth. The induction of Akt1 kinase activity, via Ser 473, was dependent upon a single residue of cyclin D1 (K112) in vitro, and in vivo in mammary epithelial cell targets tissue specific transgenic mice. Distinct subcellular compartments of cell cycle proteins convey distinct functions to augment cellular growth.

Our data identified the function of the membrane associated cyclin D1 pool is to phosphorylate and activate AKT1, thereby, inducing cell cycle progression, contact independent growth and cellular migration. Membrane mounted cyclin D1 is a novel targetable vulnerability aberrant growth control.

Citation Format: Xuanmao Jiao, Ke Chen, Shaohua Xu, Xiaoming Ju, Adam Ertel, Lifeng Tian, Zuoren Yu, Gabriele Di Sante, Min Wang, Zhiping Li, Timothy Pestell, Mathew Casimiro, Duanwen Shen, Samuel Achilefu, Richard Pestell. The membrane associated cyclin D1 promotes contact-independent growth via phosphorylation of Akt1 Ser 473. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; Feb 28-Mar 2, 2016; Orlando, FL. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(11_Suppl):Abstract nr B33.

Abstract B10: Cyclin D1 restrains oncogene-induced autophagy via phosphorylation of LKB1

Cyclin D1 is an important molecular driver of many human cancers. The cyclin D1 gene is amplified or overexpressed in up to half of human breast cancers and mammary-targeted overexpression of cyclin D1 is sufficient to induce mammary tumorigenesis in mice. Cyclin D1 encodes the regulatory subunit of the cyclin-dependent kinase (CDK) holoenzyme that phosphorylates several substrates including the retinoblastoma protein (pRb) to advance the G1S cell cycle checkpoint and promote DNA synthesis. Recent studies have implicated cell cycle regulators that govern G1S transition, in regulating cellular metabolism. Cyclin D1 phosphorylates and inactivates a nuclear encoded protein essential for mitochondrial biogenesis, Nrf1. In this manner cyclin D1 coordinates both nuclear and mitochondrial functions. Consistent with cyclin D1-dependent inhibition of mitochondrial biogenesis, pRB promotes and E2F-1 inhibits mitochondrial biogenesis. In addition to inhibiting mitochondrial biogenesis, cyclin D1 inhibits mitochondrial membrane potential, which may be in part due to binding VDAC.

Autophagy is a catabolic pathway activated in response to cellular stress such as oxidative or nutritional stress. It mitigates cellular damage via removal of insoluble and damaged proteins, lipids and organelles. Autophagy is enhanced by the phosphorylated and activated form of 5’-AMP-activated protein kinase (AMPK). We initiated the following study to directly test the effect of cyclin D1 has on cellular metabolism and autophagy. Herein, endogenous cyclin D1 restrained autophagy in breast cancer cells in tissue culture and in the mammary gland of mice. Using mammary epithelial-targeted deletion of cyclin D1 we show cyclin D1 restrains autophagy by reducing AMPK activation. Cyclin D1 may serve to couple cellular proliferation to cellular energy homeostasis.

Citation Format: Mathew Casimiro, Gabriele Di Sante, Emanuele Loro, Timothy Pestell, Sara Bisetto, Marco Velasco-Velázquez, Xuanmao Jiao, Zhiping Li, Chenguang Wang, Daniel Ly, Bin Zheng, Shen Che-Hung, Adam Ertel, Richard G. Pestell. Cyclin D1 restrains oncogene-induced autophagy via phosphorylation of LKB1. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr B10.

A novel tridentate bis(phosphinic acid)phosphine oxide based europium(III)-selective Nafion membrane luminescent sensor

A new europium(III) membrane luminescent sensor based on a new tridentate bis(phosphinic acid)phosphine oxide (3) system has been developed. The synthesis of this new ligand is described and its full characterization by NMR, IR and elemental analyses is provided. The luminescent complex formed between europium(III) chloride and ligand 3 was evaluated in solution, observing that its spectroscopic and chemical characteristics are excellent for measuring in polymer inclusion membranes. Included in a Nafion membrane, all the parameters (ligand and ionic additives) that can affect the sensitivity and selectivity of the sensing membrane as well as the instrumental conditions were carefully optimized. The best luminescence signal (λexc = 229.06 nm and λem = 616.02 nm) was exhibited by the sensing film having a Nafion : ligand composition of 262.3 : 0.6 mg mL(-1). The membrane sensor showed a short response time (t95 = 5.0 ± 0.2 min) and an optimum working pH of 5.0 (25 mM acetate buffer solution). The membrane sensor manifested a good selectivity toward europium(III) ions with respect to other trivalent metals (iron, chromium and aluminium) and lanthanide(III) ions (lanthanum, samarium, terbium and ytterbium), although a small positive interference of terbium(III) ions was observed. It provided a linear range from 1.9 × 10(-8) to 5.0 × 10(-6) M with a very low detection limit (5.8 × 10(-9) M) and sensitivity (8.57 × 10(-7) a.u. per M). The applicability of this sensing film has been demonstrated by analyzing different kinds of spiked water samples obtaining recovery percentages of 95-97%.

Understanding the directed ortho lithiation of (R)-Ph2P(NCO2Me)NHCH(Me)Ph. NMR spectroscopic and computational study of the structure of the N-lithiated species

The multinuclear magnetic resonance and computational study of the structure of N-lithium (R)-Ph₂P(NCO₂Me)NHCH(Me)Ph revealed the origin of its diastereoselective ortho lithiation.

Abstract 5176: PPARγ acetylation governs differentiation function

The peroxisome proliferator-activator receptor gamma (PPARγ) is a member of nuclear receptors (NRs) that plays an important role in the pathogenesis of human diseases, including obesity, type II diabetes and cancer. PPARγ regulates lipid homeostasis by activating the transcription of key genes that are responsible for lipid biosynthesis. NRs undergo post-translational modification including phosphorylation and acetylation. Direct nuclear receptor acetylation by histone acetyltransferases regulates ligand sensitivity and growth properties. Using mass spectrometry and in vivo labeling assays we showed that PPARγ is acetylated in cultured cells. Inhibition of endogenous TSA-sensitive and NAD-dependent deacetylase activity enhanced Pparγ acetylation. SIRT1 bound and deacetylated Pparγ at K154/155. These lysine residues of Pparγ were required for adipocyte differentiation function and determined distinct gene expression signaling pathways. The lysine residues governing sumoylation (K77) and acetylation (K154/155) were shown to have dissociable functions in regulating cell-cycle, gene expression, gene promoter activity, and protein stability. Breast tumor growth, de novo lipid synthesis, induction of autophagy and evasion of apoptosis was promoted by K154/155 and inhibited by K77 in vivo. Pparγ acetylation induced a gene signature that was increased in breast cancer, associated with a reduction in SIRT1 abundance and poor outcome. These studies suggest that the Pparγ lysine motif regulates both ligand-dependent receptor stability and receptor-dependent gene expression and cell functions. Pparγ and SIRT1 signaling converge in vivo to regulate breast tumor lipid metabolism and growth.

Citation Format: Lifeng Tian, Chenguang Wang, Fred K. Hagen, Mathew Casimiro, Anthony A. Sauve, Richard G. Pestell. PPARγ acetylation governs differentiation function. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5176. doi:10.1158/1538-7445.AM2013-5176

Examining the role of cyclin D1 in breast cancer

Cyclin D1 overexpression is found in more than 50% of human breast cancers and causes mammary cancer in transgenic mice. Dysregulation of cyclin D1 gene expression or function contributes to the loss of normal cell cycle control during tumorigenesis. Recent studies have demonstrated that cyclin D1 conducts additional specific functions to regulate gene expression in the context of local chromatin, promote cellular migration and inhibit mitochondrial metabolism. It is anticipated that these additional functions contribute to the pathology associated with dysregulated cyclin D1 abundance. This article discusses evidence that examines the significance of cyclin D1 in breast cancer with emphasis on its role in breast cancer stem cell expansion.

Abstract 202: Endogenous c-jun inhibits mammary epithelial cellular apoptosis in vivo

c-jun, which is overexpressed in a number of human cancers encodes a critical component of the AP-1 complex. c-jun has been shown to either induce or inhibit cellular apoptosis. Germ line deletion of both c-jun alleles is embryonically lethal. To determine the role of the endogenous c-jun gene in apoptosis, we performed mammary epithelial cell-targeted somatic deletion using floxed c-jun (c-jun f/f) conditional knockout mice. Laser capture microdissection demonstrated endogenous c-jun inhibits expression of apoptosis inducing genes and reactive oxygen species (ROS)-reducing genes (MnSOD, catalase). ROS have been implicated in apoptosis and undergo enzymatic elimination via MnSOD and CuZnSOD with further detoxification via catalase. c-jun-mediated survival was in part dependent on ROS production. c-jun-mediated repression of MnSOD and catalase occurred via mitochondrial complex I and NOX I. Collectively, these studies define a pivotal role of endogenous c-jun in promoting cell survival via maintaining mitochondrial integrity and expression of the key regulators of ROS production.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 202. doi:10.1158/1538-7445.AM2011-202

Clinical databases and data protection: are they compatible?

In the current climate of clinical governance and audit, and in the setting of an active academic unit, an effective clinical database is an invaluable tool. In this article, we will present our neurovascular database, discuss the issues related to setting up the ideal clinical database, discuss the problems related to accurate data input and review the legal requirements of data protection. The success of a clinical database is reflected by the completeness of the data, the accessibility of the information and how useful it has proven to be. After 4 years of experimentation we currently use a database designed on Microsoft Access. The form is a single page. Junior medical staff input the information as medical staff have been found to be the most reliable personnel for data input in terms of accuracy. However, time is generally in short supply amongst this group. For our purposes, the ideal database is one that is simple, that can be used to flag up cases, rather than provide all of the information and ensures a complete dataset. The arrival of the UK 1998 Data Protection Act has put many clinical databases and registries in jeopardy, and introduced further bureaucracy to research. We discuss the Act and its interpretation by the General Medical Council, Medical Research Council, British Medical Association, Department of Health and our own trust with respect to databases and research.

A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1

Loss of function at the Pten tumor-suppressor locus is a common genetic modification found in human prostate cancer. While recent in vivo and in vitro data support an important role of aberrant ErbB-2 signaling to clinically relevant prostate target genes, such as cyclin D1, the role of Pten in ErbB-2-induced prostate epithelial proliferation is not well understood. In the Pten-deficient prostate cancer cell line, LNCaP, restoration of Pten was able to inhibit ErbB-2- and heregulin-induced cell cycle progression, as well as cyclin D1 protein levels and promoter activity. Previously, we established that probasin-driven ErbB-2 transgenic mice presented with high-grade prostate intraepithelial neoplasia and increased nuclear cyclin D1 levels. We show that mono-allelic loss of pten in the probasin-driven-ErbB-2 model resulted in increased nuclear cyclin D1 and proliferating cell nuclear antigen levels and decreased disease latency compared to either individual genetic model and, unlike the probasin-driven-ErbB-2 mice, progression to adenocarcinoma. Activated 3-phosphoinositide-dependent protein kinase-1 was observed during cancer initiation combined with the activation of p70S6K (phospho-T389) and inactivation of the 4E-binding protein-1 (phosphorylated on T37/46) and was primarily restricted to those cases of prostate cancer that had progressed to adenocarcinoma. Activation of mTOR was not seen. Our data demonstrates that Pten functions downstream of ErbB-2 to restrict prostate epithelial transformation by blocking full activation of the PDK1 signaling cascade.

ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo

The receptor tyrosine kinase ErbB-2 plays an important role in the regulation of growth factor-induced signal transduction cascades in the epithelium, and ErbB-2 is frequently overexpressed in epithelial tumors. Our previous studies on clinical prostate cancer specimens indicated that ErbB-2 expression was increased in patients undergoing hormone ablation therapy. We had also shown that the critical cell cycle regulatory gene cyclin D1 and its promoter were targets of proliferative signaling in prostate cancer cell lines, and that cyclin D1 was required for ErbB-2-induced mammary tumorigenesis. In the current studies, we found that increased ErbB-2 membrane expression correlated with increased nuclear cyclin D1 staining in clinical prostate cancer specimens, and that expression of ErbB-2 was capable of inducing cell cycle progression in human prostate cancer cell lines. We further showed that ErbB-2 induced the cyclin D1 promoter in DU145 cells, and that small interfering RNA knockdown of cyclin D1 protein levels blocked a significant proportion of the heregulin-induced cell cycle progression in LNCaP cells. Probasin promoter-targeted expression of an activated ErbB-2 isoform induced cyclin D1 expression in the mouse prostate, commensurate with prostate intraepithelial neoplasia. Together, these in vitro and in vivo studies identify cyclin D1 as a critical downstream target of ErbB-2 in the prostate epithelium, both of which are possible therapeutic targets for cancer intervention. Furthermore, our novel mouse model provides a useful platform for ongoing in vivo investigations of ErbB-2 signaling in the prostate epithelium.

Kcnq1 contributes to an adrenergic-sensitive steady-state K+ current in mouse heart

It has been suggested that Kcne1 subunits are required for adrenergic regulation of Kcnq1 potassium channels. However, in adult mouse hearts, which do not express Kcne1, loss of Kcnq1 causes a Long QT phenotype during adrenergic challenge, raising the possibility that native Kcnq1 currents exist and are adrenergically regulated even in absence of Kcne1. Here, we used immunoblotting and immunohistochemical staining to show that Kcnq1 protein is present in adult mouse hearts. Voltage-clamp experiments demonstrated that Kcnq1 contributes to a steady-state outward current (I(SS)) in wild-type (Kcnq1(+/+)) ventricular myocytes during isoproterenol stimulation, resulting in a significant 7.1% increase in I(SS) density (0.43+/-0.16 pA/pF, p <0.05, n =15), an effect that was absent in Kcnq1-deficient (Kcnq1(-/-)) myocytes (-0.14+/-0.13 pA/pF, n =17). These results demonstrate for the first time that Kcnq1 protein is expressed in adult mouse hearts where it contributes to a beta-adrenergic-induced component of I(SS) that does not require co-assembly with Kcne1.

In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models

BACKGROUND

Mouse prostate cancer modeling presents unique obstacles to the study of spontaneous tumor initiation and progression due to the anatomical location of the tissue.

RESULTS

High resolution (130 microm(x) x 130 microm(y) x 300 microm(z)), three-dimensional MRI allowed for the visualization, segmentation, and volumetric measurement of the prostate from normal and genetically engineered animals, in vivo. Additionally, MRS performed on the prostate epithelia of probasin-ErbB-2Delta x Pten(+/-) mice identified changes in the relative concentrations of the metabolites choline and citrate, which was not observed in TRAMP mice.

METHODS

T1-weighted MRI was performed on normal, TRAMP, probasin-ErbB-2/Her2/Neu (probasin-ErbB-2Delta), and probasin-ErbB-2Delta in the context of decreased Pten activity (probasin-ErbB-2Delta x Pten(+/-)) mice. Volume-localized single-voxel proton magnetic resonance spectroscopy (SVS (1)H MRS) was also performed.

CONCLUSIONS

The data presented supports the use of combined MRI and MRS for the measurement of biochemical and morphometric alterations in mouse models of prostate cancer.

Contrast-Enhanced In Vivo Imaging of Breast and Prostate Cancer Cells by MRI

The development of effective cancer therapies has been hampered, in part, by the inability to noninvasively follow tumor progression from the initial cancerous lesion through to metastasis. We have previously shown that superparamagnetic iron oxide particles can be used as magnetic resonance imaging contrast agents to label embryonic, mesenchymal and hematopoietic stem cells in vivo. Improving the capacity to non-invasively image cancer progression is an appealing method that could be useful for assessing the efficacy of anticancer therapies. We have established that human prostate (LNCaP, DU145, PC3), rodent prostate (TRAMPC1, YPEN-1), human breast (MDA-MB-231) and mouse mammary (Myc/VEGF) cancer cell lines were readily labeled by fluorescent superparamagnetic sub-micron particles of iron oxide (MPIOs). The MPIOs were essentially inert with respect to cell proliferation and tumor formation. Fluorescence stereomicroscopy and three dimensional magnetic resonance imaging (MRI) determined that subcutaneous, intramuscular or orthotopically implanted labeled cancer cells could be imaged, in vivo, despite in some cases being undetectable by manual palpation. The MPIO-labeled cancer cells could also be imaged, in vivo, at least 6 weeks after implantation. The fluorescent MPIOs further allowed for the ex vivo identification of tumors cells from histological sections. This study demonstrates the feasibility of using fluorescent MPIOs in prostate and breast cancer cell lines as both a negative contrast agent for in vivo MRI as well as a fluorescent tumor marker for optical imaging in vivo and ex vivo.

The RpoN-box motif of the RNA polymerase sigma factor sigma N plays a role in promoter recognition

The RNA polymerase sigma factor sigma N (sigma 54) is characterized by the presence, near the C-terminal end of the protein, of a highly conserved sequence of 10 amino acids (ARRTVAKYRE) that has been termed the RpoN box. In order to examine the function of this motif, which is predicted to adopt an alpha-helical structure, we have isolated a number of mutations that alter residues within the box and examined the properties of the sigma N derivatives encoded by them. Certain mutations that alter charged and potentially exposed residues within the motif result in transcriptionally inactive proteins with impaired promoter recognition but no impairment in core RNA polymerase binding. We therefore suggest that the RpoN box could play a direct or indirect role in recognition of the -24, -12 promoter consensus that is characteristic of sigma N-dependent genes.

Medicine: the first step on the road to holiness?

The connections of Medicine and Religion are thoroughly documented in the primitive societies, and it comes as no surprise to see them together. Here we describe the true story of a Portuguese physician of the late 19th century whose image today is venerated in such a way as to compare him to a saint and to bestow upon him miraculous powers of healing. We propose that modern day physicians can learn from the example of this man that the role of doctor encompasses not only scientific and technical mastery but, most of all, piety, humanity and compassion.